By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Amplyx Pharmaceuticals 

12730 High Bluff Drive
Suite 160
San Diego  California  92130  U.S.A.
Phone: 858-345-1755 Fax: 858-345-1346


SEARCH JOBS

Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening invasive fungal infections due to candida, aspergillus and rare molds.

Patients undergoing chemotherapy and other immunosuppressive treatments end up with compromised immune systems. This makes them susceptible to a new disease—invasive fungal infections. By treating their underlying condition, patients are now open to a new life-threatening disease.

Yet, existing therapies for invasive fungal infections are extremely limited on many fronts—they’re difficult to administer, can have toxic side effects and are ineffective against more potent fungi which have developed resistance.

Amplyx is advancing a novel small-molecule therapy, APX001, in clinical development. The Phase 1 program is evaluating APX001 using both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from hospital.


Key Statistics


Email: info@amplyx.com
Ownership: Private

Web Site: Amplyx
Employees:
Symbol: 
 



Industry
Biotechnology

Segment
Biotechnology





Company News
San Diego’s Amplyx Bags $67 Million to Advance APX001 into Clinical Development 8/2/2017 7:03:30 AM
San Diego's Amplyx Names A New CEO 1/6/2017 7:42:40 AM
Amplyx Appoints Ciara Kennedy, Ph.D., As President And Chief Executive Officer 1/5/2017 7:46:45 AM
FDA Grants Orphan Drug Designation To Amplyx For APX001 For Treatment Of Multiple Invasive Fungal And Mold Infections 11/16/2016 11:03:38 AM
Amplyx Initiates Dosing In Phase 1 Clinical Trial Of APX001, A Novel Antifungal Product Candidate For Treatment Of Life-Threatening Infections 9/12/2016 6:21:35 AM
Amplyx Announces Qualified Infectious Disease Product Designation For APX001 In Three Life-threatening Fungal Infections 6/15/2016 10:18:17 AM
Amplyx Appoints Paul C. Grint, M.D., To Board Of Directors 5/24/2016 6:42:01 AM
SoCal's Amplyx Ups Series B Financing to $49.2 Million and Beefs Up Executive Team 2/9/2016 6:11:14 AM
San Diego’s Amplyx Bags $41 Million to Fight a Deadly Fungus 11/11/2015 6:26:49 AM
Amplyx Pharmaceuticals Announces Completion And Extension Of Series A Preferred 4/8/2010 8:58:13 AM
12
//-->